Company intelligence / Profile preview

Find Therapeutics

Saint-Laurent / Montreal area, Quebec, Canadafindtherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Find Therapeutics is a clinical-stage biopharmaceutical company developing precision therapies for autoimmune diseases. Its lead candidate, FTX‑101, is in Phase 1 trials as a remyelinating agent with a novel mechanism aimed at repairing myelin in autoimmune conditions. The company leverages exclusive GPCR-targeting technologies licensed from academic partners.

Therapeutic areas: Rare DiseasesImmunology
Modalities: Small molecules (implied by focus on membrane receptor targeting and GPCR technology)Potentially peptide-based agents (inferred from technology licensed from Peptimimesis Pharma and University of Strasbourg)
Industry: Biotech

Drug pipeline

1 asset

tasronetide

Unknown

Partnerships

SATT-Conectus and University of Strasbourg (technology license)

Beyond the preview

Go deeper on Find Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Find Therapeutics.